×
About 733 results

ALLMedicine™ Prolactinoma Center

Research & Reviews  274 results

Determinants of surgical remission in prolactinomas: a systematic review and meta-analy...
https://doi.org/10.1016/j.wneu.2021.07.035
World Neurosurgery; Wright K, Chaker L et. al.

Jul 30th, 2021 - Prolactin secreting tumors respond well to medical management with a small fraction of patients requiring surgery. We conducted a systematic review and meta-analysis to study the determinants of surgical remission in these tumors. We searched PubM...

Surgery is a safe, effective first-line treatment modality for noninvasive prolactinomas.
https://doi.org/10.1007/s11102-021-01168-x 10.1001/jama.2016.19699 10.1007/s11102-012-0454-0 10.1210/jc.2010-0537 10.1016/j.beem.2019.101290 10.3803/EnM.2020.35.2.237 10.1210/jc.2010-1692 10.1210/jcem-60-4-698 10.1210/er.2005-9998 10.1517/14656566.1.3.555 10.1210/jcem.84.7.5810 10.1056/NEJMoa054830 10.4065/74.4.371 10.1186/s12902-020-0507-8 10.1210/clinem/dgz076 10.1210/jc.2018-02202 10.1210/jc.2008-2103 10.1007/s11102-010-0283-y 10.3171/2011.1.FOCUS10317 10.1530/EJE-07-0248 10.3803/EnM.2014.29.3.280 10.1016/j.wneu.2016.08.088 10.3171/jns.2002.97.2.0307 10.1007/s11102-019-01001-6 10.1111/j.1365-2265.2006.02493.x 10.1136/bmj.2.5816.743 10.1056/NEJM199410063311403 10.1210/jc.2009-1238 10.1210/clinem/dgaa744 10.1111/cen.13339 10.1007/s40618-020-01478-0 10.3389/fendo.2015.00085 10.1007/s11102-010-0261-4 10.1136/bcr-2017-220971 10.1530/EJE-16-0087 10.3389/fendo.2018.00636 10.1210/clinem/dgz144 10.1007/s40618-021-01569-6 10.3346/jkms.2021.36.e97 10.1210/jcem.87.7.8645 10.1055/a-1247-4908 10.1159/000180098 10.1007/s11102-019-01016-z 10.3389/fendo.2020.00439 10.1016/j.clineuro.2013.02.016 10.1007/s11102-018-0904-4 10.1007/s12020-016-1115-2
Pituitary Park JY, Choi W et. al.

Jul 1st, 2021 - Dopamine agonists (DAs) have long been the recommended first-line treatment for prolactinoma. Given the remarkable developments in surgical techniques, however, surgery is on the rise. We compared the treatment outcomes of patients with noninvasiv...

Computational study on new natural compound agonists of dopamine receptor.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266345
Aging Li H, Yang W et. al.

Jun 26th, 2021 - Dopamine receptor, a polypeptide chain composed of 7 hydrophobic transmembrane regions, is a new and vital drug target, especially Dopamine receptor 2(D2). Targeting dopamine receptors, Dopamine receptor agonists are a class of drugs similar in fu...

Is there an increased cardiovascular risk in patients with prolactinoma? A challenging ...
https://doi.org/10.1002/jcu.23030
Journal of Clinical Ultrasound : JCU; Yazici D, Sunbul M et. al.

Jun 17th, 2021 - Epicardial adipose tissue thickness (EATT) is considered to be a surrogate for visceral fat and a novel cardiovascular risk indicator. Hyperprolactinemia has been shown to be associated with increased cardiovascular risk. The aim was to evaluate t...

Pituitary apoplexy of a giant prolactinoma during pregnancy.
https://doi.org/10.1080/09513590.2021.1938527
Gynecological Endocrinology : the Official Journal of The... Khaldi S, Saad G et. al.

Jun 15th, 2021 - Prolactinomas are a common cause of sexual dysfunction and infertility. We aimed, through this case report, to illustrate the difficulties of management of women with giant prolactinoma, especially in cases of desire of pregnancy. A 30-year-old wo...

see more →

Guidelines  1 results

Pituitary incidentaloma: an endocrine society clinical practice guideline.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5393422
The Journal of Clinical Endocrinology and Metabolism; Freda PU, Beckers AM et. al.

Apr 9th, 2011 - The aim was to formulate practice guidelines for endocrine evaluation and treatment of pituitary incidentalomas. Consensus was guided by systematic reviews of evidence and discussions through a series of conference calls and e-mails and one in-per...

see more →

Clinicaltrials.gov  8 results

Bromocriptine Quick Release (BCQR) as Adjunct Therapy in Type 1 Diabetes
https://clinicaltrials.gov/ct2/show/NCT02544321

Jun 17th, 2019 - Type 1 diabetes (T1D) continues to be a disease plagued by hyperglycemia, insulin resistance (IR), and increased cardiovascular disease (CVD) despite advances in insulin delivery and glucose monitoring. Therefore new approaches are needed. Bromocr...

Dopamine D2 Receptors(D2R) Imaging in Prolactinomas
https://clinicaltrials.gov/ct2/show/NCT03717454

Nov 20th, 2018 - The dopamine agonist(DA),such as cabergoline(CAB) and bromocriptine(BC), has been used widely in the treatment of prolactinomas, but its clinical use is hampered by intolerance and/or resistant in some patients. It had been showed that DA inhibit ...

Dopamine D2 Receptors(D2R) Imaging in Nonfunctioning Pituitary Adenoma(NFPA)
https://clinicaltrials.gov/ct2/show/NCT03714763

Oct 22nd, 2018 - Dopamine agonists are the first line therapy for prolactinoma,which are also effective in some cases of other subtypes of pituitary tumors. It had been showed that dopamine agonists inhibit prolactin secretion by binding to and activating dopamine...

Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas
https://clinicaltrials.gov/ct2/show/NCT03400865

Oct 16th, 2018 - The dopamine agonist cabergoline (CAB) has been used widely in the treatment of prolactinomas, but its clinical use is hampered by intolerance and/or resistant in some patients with prolactinoma. Chloroquine (CQ) is an old drug widely used to trea...

Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors)
https://clinicaltrials.gov/ct2/show/NCT03043508

Feb 6th, 2018 - Retrospective review of a prospectively maintained MEN1 database. The patient cohort consists of all patients with confirmed MEN1 with or without PNET who are included in the database. The database will be reviewed to obtain patient and disease ch...

see more →

News  7 results

Prolactin, the pituitary, and pregnancy: Where’s the balance?
https://www.mdedge.com/familymedicine/article/164370/pituitary-thyroid-adrenal-disorders/prolactin-pituitary-and-pregnancy/page/0/3
Clinical Endocrinology News;

Apr 26th, 2018 - What if the tumor grows in pregnancy? During pregnancy, high estrogen levels from the placenta can stimulate prolactinoma growth, and the dopamine agonist’s inhibitory effect is gone once that medication’s been stopped. This means that “We have bo.

Pituitary Incidentaloma
https://www.mdedge.com/clinicianreviews/article/96669/endocrinology/pituitary-incidentaloma/page/0/1

Jan 26th, 2015 - SHOULD AN ASYMPTOMATIC PATIENT BE EVALUATED FURTHER? Endocrine Society guidelines2 recommend that all patients with pituitary incidentaloma, with or without symptoms, should undergo a complete history and physical examination and laboratory evalua.

Prolactinoma: A Case Study
https://www.mdedge.com/clinicianreviews/article/72153/endocrinology/prolactinoma-case-study/page/0/1

Nov 1st, 2011 - Dopamine agonists are approximately 80% to 90% effective in decreasing prolactin levels and reducing tumor size in microadenomas and 60% to 70% in macroadenomas. The major drawback of using medication is that it does not always provide permanent r.

Endocrine Society Releases Guidelines on Pituitary Incidentalomas
https://www.mdedge.com/internalmedicine/article/34059/endocrinology/endocrine-society-releases-guidelines-pituitary
Elizabeth Mechcatie

Apr 20th, 2011 - Surgical treatment of a pituitary incidentaloma is recommended when the lesion is causing a visual field deficit or other visual abnormalities, such as ophthalmoplegia "or neurological compromise," according to evidence-based clinical practice gui.

The Case of the Famous Woman With a Bloated Belly
https://www.medscape.com/viewarticle/714607_4

Jan 11th, 2010 - How Would Mary Have Been Treated Today? Today, when a woman suspects pregnancy, she undergoes a rapid test for pregnancy. If the result is negative but symptoms, such as galactorrhea or amenorrhea, are still present, an occult prolactinoma might b...

see more →

Patient Education  3 results see all →